文献速递胸部肿瘤

帕唑帕尼或安慰剂用于完全切除的I期非小细胞肺癌患者:II期IFCT-0703试验结果

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
PubMed 文献 · Ann Oncol · 2017-01-01

这项双盲II/III期试验将完全切除的I期非小细胞肺癌患者随机分配至安慰剂或帕唑帕尼800 mg/日组,因依从性不足经中期分析后降至400 mg/日。帕唑帕尼800 mg/日依从性为38%,400 mg/日增至69%(P=0.027);3年无复发生存率帕唑帕尼组76% vs 安慰剂组83%(HR=1.3,P=0.53),5年总生存率83% vs 94%(HR=1.8,P=0.26)。结论认为400 mg/日可行但可能低于治疗剂量,未能改善无复发生存。

要点

  • 帕唑帕尼800 mg/日依从性仅38%,降至400 mg/日后依从性为69%(P=0.027)。
  • 3年无复发生存率帕唑帕尼组76% vs 安慰剂组83%(HR=1.3,95%CI 0.6-2.7,P=0.53)。
  • 5年总生存率帕唑帕尼组83% vs 安慰剂组94%(HR=1.8,95%CI 0.6-5.5,P=0.26)。

核心结论

  • 在完全切除的I期非小细胞肺癌患者中,辅助帕唑帕尼400 mg/日可行但800 mg/日不可行,400 mg/日可能低于治疗剂量,且未能改善无复发生存。

研究设计与样本

  • 双盲II/III期试验,完全切除的I期非小细胞肺癌患者随机分配至安慰剂或帕唑帕尼800 mg/日组,计划治疗6个月,采用两步Fleming设计。
  • 中期分析纳入64例患者后,独立数据监查委员会因依从性不足建议将帕唑帕尼降至400 mg/日,并改用一步Fleming设计;每组各入组71例患者。

主要发现

  • 患者中61%为男性,91%为吸烟者,中位年龄60岁,80%为病理IA期,16%为鳞状细胞癌。
  • 帕唑帕尼800 mg/日依从性为38%(95%CI 23-55),400 mg/日依从性为69%(95%CI 50-84;P=0.027)。
  • 帕唑帕尼800 mg/日组有2例患者发生4级毒性;最常见的3级毒性在800 mg/日组为转氨酶升高(16%)、高血压(13%)和腹泻(9%),在400 mg/日组为胃肠道疾病(16%;其中腹泻6%)和高血压(6%)。
  • 中位随访47个月,3年无复发生存率帕唑帕尼组为76%(95%CI 65%-86%),安慰剂组为83%(95%CI 74%-92%),风险比=1.3(95%CI 0.6-2.7),P=0.53。
  • 5年总生存率帕唑帕尼组为83%(95%CI 72-94),安慰剂组为94%(95%CI 88-100),风险比=1.8(95%CI 0.6-5.5),P=0.26。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant treatment in resected stage I non-small-cell lung cancer (NSCLC) is generally not recommended. Pazopanib is an oral tyrosine kinase inhibitor of VEGFR-1/2/3 and PDGFR-α/β. We explored the feasibility and efficacy of adjuvant pazopanib in this population. PATIENTS AND METHODS: In this double-blind phase II/III trial, patients with resected stage I NSCLC were randomized to placebo or pazopanib 800 mg/day (P800) for 6 months with a two-step Fleming design. The primary endpoint was compliance (percentage of patients receiving ≥3 months pazopanib). From the interim analysis after 64 patients were included, the IDMC recommended reducing to pazopanib 400 mg/day (P400) due to insufficient compliance, with a one-step Fleming. Although unplanned, survival data were analyzed. RESULTS: A total of 71 patients were enrolled in each arm; 61% were male, 91% were smokers, median age was 60 years, 80% had pathological stage IA, and 16% had squamous cell carcinoma. Pazopanib compliance was 38% [95% confidence interval (CI) 23-55] with P800, increasing to 69% (95% CI 50-84; P = 0.027) with P400. Two patients had grade 4 toxicities with P800. The most common grade 3 toxicities were increased transaminases (16%), hypertension (13%), and diarrhea (9%) with P800, and gastrointestinal disorders (16%; 6% diarrhea) and hypertension (6%) with P400. Median follow-up was 47 months. Three-year recurrence-free survival was 76% (95% CI 65%-86%) with pazopanib and 83% (95% CI 74%-92%) with placebo [hazard ratio = 1.3 (95% CI 0.6-2.7), P = 0.53]. Five-year overall survival was 83% (95% CI 72-94) with pazopanib and 94% [95% CI 88-100] with placebo [hazard ratio = 1.8 (95% CI 0.6-5.5), P = 0.26]. CONCLUSIONS: In resected stage I NSCLC patients adjuvant 400 mg/day pazopanib but not 800 mg/day was feasible, although possibly infra-therapeutic and failed to improve relapse-free survival.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Besse B, Mazières J, Ribassin-Majed L, et al. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Ann Oncol. 2017. PMID: 28327934. doi:10.1093/annonc/mdx070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。